Methods 24 subjects with type 2 diabetes treated with diet and/or metformin were randomised in a double blind study to receive 30mg pioglitazone, 8mg rosiglitazone or placebo once daily for 3 months. Before and after treatment absolute secretion rate (ASR) and fractional catabolic rate (FCR) of VLDL, IDL and LDL apolipoprotein B100 were measured with a 10 hour infusion of 1-13 C leucine. 
Introduction
The peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists pioglitazone and rosiglitazone were introduced in Europe in 2000 and the USA in 1999 for the treatment of type 2 diabetes [1] . As well as reducing blood glucose and HbA1c there is also evidence that these PPAR-γ agonists affect plasma lipid levels [2] . Since dyslipidaemia in diabetes contributes to the increased risk of macrovascular disease the effect of these drugs on dyslipidaemia is important. Interest in this has increased recently since the publication of a meta-analysis suggesting increased cardiovascular risk with rosiglitazone. The authors postulated that the adverse effect of rosiglitazone on plasma lipids may be a possible mechanism behind this increased risk [3] .
Large double-blinded, placebo controlled studies of rosiglitazone show that it increases total, high density lipoprotein (HDL) and low density lipoprotein (LDL) cholesterol with no effect on triglyceride levels [4] [5] [6] . Similar studies with pioglitazone have found an increase in HDL cholesterol, a less consistent increase in LDL and total cholesterol and a reduction in triglyceride [7] [8] [9] . Systematic reviews [10] [11] have confirmed these differences. In the only head to head study 802 subjects with type 2 diabetes were randomised to pioglitazone 45mg or rosiglitazone 8mg for 24 weeks [12] . In the pioglitazone group there was a 12% reduction in triglyceride after 24 weeks treatment. In contrast in the rosiglitazone group there was an increase in triglyceride levels. HDL cholesterol and LDL cholesterol increased in both groups but the increase in HDLcholesterol was greater in the pioglitazone group and the increase in LDL-cholesterol was greater in the rosiglitazone group. There was no difference in the effect on HbA1c or cardiovascular parameters.
The different effects of rosiglitazone and pioglitazone on lipid levels have yet to be explained. Lipoprotein turnover studies provide a methodology for investigating the mechanism behind changes in lipid concentrations. Several studies have investigated the effects of PPAR-γ agonists on lipoprotein turnover. The first, [13] Samples for VLDL, IDL and LDL were separated by sequential density ultracentrifugation in a Beckman Coulter Optima LE80-K ultracentrifuge (High Wycombe, UK) with a type 50.4 Ti fixed angle rotor as previously described [17] . LDL2
and LDL3 subfractions were separated from a baseline LDL fraction by adjusting the density to 1.044g/l then ultracentrifugation for 20h and removal of the top 1ml (LDL2).
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The bottom fraction was then adjusted to density 1.063g/l followed by ultracentrifugation for 20h and removal of the top 1ml (LDL3).
VLDL, IDL and LDL apo B was precipitated by isopropanol [18] , and hydrolysed using hydrochloric acid. VLDL and IDL samples were derivatised with N-methyl-N-(tertbutyldimethylsilyl)-trifluoroacetamide (MTBSTFA) VLDL and IDL apo B enrichment was measured using gas chromatography mass spectrometry (GCMS), Since the isotopic enrichment of LDL apo B is much lower than VLDL and IDL this was determined using a N-acetyl n-propyl ester derivative on a gas chromatography combustion isotope ratio mass spectrometer (GC-C-IRMS), specifically a Sira Series 2
IRMS (VG Instruments, Hellingly, UK) coupled to an Orchid Gas Chromatograph
Interface Module (Europa Scientific, Crewe, UK). Data were analysed using the manufacturer's software (Orchid Post Processor, Version 2.3c. Europa Scientific).
Isotope abundance was expressed relative to pulse peaks of reference CO 2 gas. The Plasma volume was calculated using the method of Pearson [20] .
Power calculation
The primary endpoint was the change in VLDL secretion rate from baseline for each treatment versus the change from baseline for placebo. We estimated that a study with 8 patients in each group would have a power of 80% to detect a difference of 45% in the production rate of VLDL at the 5% level of significance. For this calculation it was assumed that the standard deviation in production rate of VLDL apo B metabolism would be 30% (ref). Since an exercise programme which improves insulin sensitivity has been shown to reduce VLDL production rate by 49% [21] , a similar order of magnitude was expected for the glitazones.
Statistical analysis
Data is presented as mean ± SEM except for non-parametrically distributed variables (triglyceride, ASR and FCR) which is presented as median (interquartile range). Prior to treatment plasma triglyceride, LDL cholesterol and HDL cholesterol were near normal. Only 6 subjects had a plasma triglyceride greater than 2.0mmol/l; 4 subjects had a LDL cholesterol greater than 3.0 mmol/l and 7 subjects had an HDL cholesterol below 1mmol/l.
There was a significant decrease in NEFAs with pioglitazone and rosiglitazone treatment 
Adiponectin
There was a significant increase in adiponectin in the pioglitazone and the rosiglitazone group following treatment (pioglitazone from 5.46µg/ml ± 1.07 to 10.34µg/ml ± 1.71, p = 0.001, and rosiglitazone from 7.33µg/ml ± 1.16 to 15.93µg/ml ± 3.40, p = 0.002). 
Discussion
This study compared the effect of placebo, pioglitazone and rosiglitazone on lipids and lipoprotein kinetics in patients with type 2 diabetes with near normal plasma lipid levels.
There was a modest improvement in HbA1c and a decrease in NEFAs with pioglitazone and rosiglitazone. Although there was no significant change in plasma triglycerides there was a decrease in VLDL triglyceride/apo B suggesting a decrease in large VLDL particles (VLDL1) with both treatments. LDL cholesterol also did not change but there was an increase in large buoyant LDL cholesterol (LDL2) and a decrease in small dense LDL (LDL3) in the rosiglitazone group. There was no significant difference in lipoprotein metabolism after treatment between the 3 groups. The only significant finding was a reduction in VLDL apo B ASR in the rosiglitazone group, however there was no difference between treatment and placebo in this or any other measurement.
The findings are surprising since previous studies have shown that the PPAR-γ agonists affect plasma lipids and that pioglitazone has a more favourable effect than rosiglitazone.
A number of mechanisms may account for this. Subjects had well controlled plasma lipids and diabetes at baseline. The most marked changes in lipids seen in studies of the thiazolidinediones tend to be in subjects with dyslipidaemia at baseline. Indeed it has been suggested that the reason that pioglitazone is thought to have a more beneficial effect on lipids is that subjects in the original pioglitazone studies had more dyslipidaemia at baseline [11] . Mean LDL cholesterol at baseline was greater than 3mmol/l in the 3 largest studies of rosiglitazone and pioglitazone [5] [6] [7] [8] [9] [22] and triglyceride was greater than 2.5mmol/L in 4 of these studies [5, [7] [8] [9] . Since the publication of trials such as the Heart Protection Study [23] the lipid concentrations in the present study are more reflective of current targets and clinical practice.
In previous studies of PPAR-γ agonists changes in lipid concentrations have been relatively small. The increase in HDL cholesterol with pioglitazone and rosiglitazone has been reported to be between 10 and 15%, the increase in LDL and total cholesterol with rosiglitazone is of a similar magnitude and the reduction in triglyceride with pioglitazone varies from 5 to 24% but is usually about 10%. In a head to head study [12] the change in triglyceride was -12% and +15%, the change in total cholesterol was +5.7% and +15.9%
and the change in HDL cholesterol was +14.9% and +7.8% with pioglitazone and rosiglitazone respectively. In a recent study in younger men without diabetes (mean age 48 years) with BMI ranging from 20.0 to 41.6 kg/m 2 and triglyceride levels between 0.61 and 4.0mmol/l rosiglitazone was shown to increase triglycerides by 32 % [15] . In contrast a number of studies have shown rosiglitazone to have no significant effect on plasma triglycerides as in the current study [4] , [5] .
Despite the lack of change in lipid levels in the current study there were changes in VLDL and LDL particle sizes. In both treatment groups there was a significant decrease in VLDL/apo B suggesting a decrease in large VLDL (VLDL1). A recent study has
shown that the increase in VLDL triglyceride in diabetes is due to an increase in VLDL1 production rate and that VLDL2 production rate is unaffected by diabetes [24] . This suggests that VLDL1 and VLDL2 are independently regulated. It has been suggested that the increased VLDL1 in type 2 diabetes results in an increase in small dense LDL and a reduction in HDL, increasing the risk of atherosclerosis [25] . However a decrease in small dense LDL (LDL3), an increase in large buoyant LDL (LDL2) and an increase in HDL cholesterol was found in the rosiglitazone treated group but not in the pioglitazone group. This effect of rosiglitazone to shift LDL phenotype from dense to large buoyant subfractions has been reported in animal [26] and human studies [27] and may explain the tendency of rosiglitazone to increase LDL cholesterol.
Despite the similar changes in VLDL triglyceride/apo B with rosiglitazone and pioglitazone there was no change in VLDL apo B ASR compared to placebo although there was a significant reduction compared to baseline in the rosiglitazone group. There was a similar decrease in NEFAs in both groups. There is evidence that increased delivery of plasma NEFAs to the liver increases hepatic triglyceride synthesis and the assembly of VLDL and that this is fundamental in the development of diabetic dyslipidaemia [28] . Since VLDL apo B ASR was not decreased compared to placebo in either treatment factors other than NEFA flux must be important in controlling VLDL apo B ASR.
A study performed in a hamster model of insulin resistance [29] showed that rosiglitazone reduced VLDL apo B secretion rate with no effect on VLDL triglyceride clearance rate with an associated reduction in expression of microsomal transfer protein.
Similarly troglitazone (600mg per day) has been shown to decrease VLDL apo B ASR with no effect on VLDL apo B FCR [13] whereas a recent study found no change in the ASR or FCR of triglyceride rich apoB in men without diabetes treated with rosiglitazone when compared to placebo [15] .
The lack of effect of pioglitazone on VLDL apo B kinetics is in keeping with previous studies. Treatment with 30-45mg of pioglitazone for 12-14 weeks in patients with type 2 diabetes was shown to have no effect on VLDL apo B kinetics [14] . The patients in this study had a much greater triglyceride than the current study (triglyceride was > 2.0mmol/l in 6 out of 8 patients) and pioglitazone reduced plasma triglyceride and VLDL triglyceride with no change in VLDL apo B suggesting a decrease in particle size as in the current study. There was an increased FCR of VLDL triglyceride, but there was no change in VLDL triglyceride ASR. Fibrates have also been shown to increase the FCR of VLDL [30] , explained by hepatic activation of PPAR-α increasing expression of lipoprotein lipase and decreasing hepatic apo CIII synthesis. Pioglitazone may thus have PPAR-α like action. The lack of this effect in the current study may be due to the lower triglyceride concentrations.
This study demonstrates that in people with diabetes and well controlled lipids that although the addition of rosiglitazone and pioglitazone had no effect of plasma triglycerides or LDL cholesterol there was a decrease in VLDL triglyceride/apo B ratio suggesting a shift from large VLDL1 to small VLDL2. In addition rosiglitazone increased large buoyant LDL and decreased small dense LDL, an effect not seen with pioglitazone.
This may explain the reported effects of rosiglitazone to increase LDL cholesterol, an effect which has been postulated to be the cause of the increased cardiovascular risk seen with this drug.
